Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Innogen (银诺医药) Pre-IPO: Thoughts on Valuation

Innogen (银诺医药) IPO: Fairly Valued at Best and Lack of Institutional Interests

Innogen (银诺医药) IPO Trading Update

Innogen (银诺医药) Pre-IPO Update: New Data Points

Innogen (银诺医药) Pre-IPO First Take: Good News Is Also Bad News

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Guangzhou Innogen Pharmaceutical Group / Equity Capital Markets

Guangzhou Innogen Pharmaceutical Group (2591 HK)

<ul>
<li>Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.</li>
<li>In this note, we look at changes to the company’s PHIP prospectus.</li>
<li>While there is no major update to the asset lists, we do see that the market forecasts provided in the prospectus scaled down significantly.</li>
</ul>


Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.
In this note, we look at changes to the company’s PHIP prospectus.
While there is no major update to the asset lists, we do see that the market forecasts provided in the prospectus scaled down significantly.


Innogen (银诺医药) Pre-IPO Update: Cuts in Market Forecasts